Top

Published in:

01-02-2015 | Clinical trial

Effect of menstrual cycle and menopausal status on apparent diffusion coefficient values and detectability of invasive ductal carcinoma on diffusion-weighted MRI

Authors: Suyoung Shin, Eun Sook Ko, Rock Bum Kim, Boo-Kyung Han, Seok Jin Nam, Jung Hee Shin, Soo Yeon Hahn

Published in: Breast Cancer Research and Treatment | Issue 3/2015

Abstract

The purpose of this study was to determine whether the apparent diffusion coefficient (ADC) and tumor detectability based on diffusion-weighted imaging (DWI) are affected by the menstrual cycle or menopausal status in breast cancer patients. Institutional review board approval was obtained, and the requirement for informed consent was waived. A total of 124 women with invasive ductal carcinoma not otherwise specified (IDC NOS) who underwent breast MRI with DWI were included in this study. Two radiologists retrospectively measured the ADCs of tumor and contralateral normal glandular tissue and scored the tumor detectability. The ADCs and detectability were compared to menstrual cycle and menopausal status, based on patient questionnaires. ADCs of tumors and contralateral tissue were significantly lower in postmenopausal women than in premenopausal women (P = 0.006 and P < 0.001, respectively). Tumor detectability did not differ significantly between the premenopausal and postmenopausal groups (P = 0.454). Normalized ADCs were not significantly lower in postmenopausal women compared to premenopausal women (P = 0.880). There was no statistically significant difference in the absolute, contralateral, and normalized ADCs (P = 0.091, 0.809, and 0.299, respectively), and the tumor detectability (P = 0.680) according to the menstrual cycle. Although ADCs of the IDC and normal glandular tissue in postmenopausal women were significantly lower than those in premenopausal women, the menstrual cycle did not affect tumor detectability and ADCs of IDC.

Partridge SC, Mullins CD, Kurland BF et al (2010) Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol 194(6):1664–1673CrossRefPubMed

Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C (2007) Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol 17(10):2646–2655CrossRefPubMed

Woodhams R, Matsunaga K, Kan S et al (2005) ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 4(1):35–42CrossRefPubMed

Woodhams R, Matsunaga K, Iwabuchi K et al (2005) Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 29(5):644–649CrossRefPubMed

Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH (2007) The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol 8(5):390–396CrossRefPubMedCentralPubMed

Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH (2008) Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 246(1):116–124CrossRefPubMed

Chen X, Li WL, Zhang YL, Wu Q, Guo YM, Bai ZL (2010) Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions. BMC Cancer 10:693CrossRefPubMedCentralPubMed

Kuhl CK, Bieling HB, Gieseke J et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203(1):137–144CrossRefPubMed

Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen CD (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203(1):145–149CrossRefPubMed

10.

O’Flynn EA, Morgan VA, Giles SL, deSouza NM (2012) Diffusion weighted imaging of the normal breast: reproducibility of apparent diffusion coefficient measurements and variation with menstrual cycle and menopausal status. Eur Radiol 22(7):1512–1518CrossRefPubMed

11.

Clendenen TV, Kim S, Moy L et al (2013) Magnetic Resonance Imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging 31(1):1–9CrossRefPubMed

12.

Abdel Razek AA, Gaballa G, Denewer A, Tawakol I (2010) Diffusion weighted MR imaging of the breast. Acad Radiol 17(3):382–386CrossRefPubMed

13.

Partridge SC, McKinnon GC, Henry RG, Hylton NM (2001) Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging 14(4):433–438CrossRefPubMed

14.

Ei Khouli RH, Jacobs MA, Mezban SD et al (2010) Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 256(1):64–73CrossRefPubMedCentralPubMed

15.

Nissan N, Furman-Haran E, Shapiro-Feinberg M, Grobgeld D, Degani H (2014) Diffusion-tensor MR imaging of the breast: hormonal regulation. Radiology 271(3):672–680CrossRefPubMed

16.

Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102–125PubMedCentralPubMed

17.

Pereira FP, Martins G, Figueiredo E et al (2009) Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol 193(4):1030–1035CrossRefPubMed

18.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed

19.

Dietel M, Ellis IO, Hofler H et al (2007) Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 451(1):19–25CrossRefPubMed

20.

Ramakrishnan R, Khan SA, Badve S (2002) Morphological changes in breast tissue with menstrual cycle. Mod Pathol 15(12):1348–1356CrossRefPubMed

21.

Erikson A, Andersen HN, Naess SN, Sikorski P, Davies CDL (2008) Physical and chemical modifications of collagen gels: impact on diffusion. Biopolymers 89(2):135–143CrossRefPubMed

22.

Ko ES, Han BK, Kim RB et al (2014) Apparent diffusion coefficient in estrogen receptor-positive invasive ductal breast carcinoma: correlations with tumor-stroma ratio. Radiology 271(1):30–37CrossRefPubMed

23.

Woodhams R, Ramadan S, Stanwell P et al (2011) Diffusion-weighted imaging of the breast: principles and clinical applications. Radiographics 31(4):1059–1084CrossRefPubMed

24.

Costantini M, Belli P, Rinaldi P et al (2010) Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 65(12):1005–1012CrossRefPubMed

25.

Razek AA, Gaballa G, Denewer A, Nada N (2010) Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 23(6):619–623CrossRefPubMed

Title: Effect of menstrual cycle and menopausal status on apparent diffusion coefficient values and detectability of invasive ductal carcinoma on diffusion-weighted MRI
Authors: Suyoung Shin
Eun Sook Ko
Rock Bum Kim
Boo-Kyung Han
Seok Jin Nam
Jung Hee Shin
Soo Yeon Hahn
Publication date: 01-02-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3278-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer

Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2′-deoxycytidine in human breast cancer cells

Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways

Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer